TGFB1 and colorectal carcinoma: It seems that cetuximab evokes immune inflammation via antibody-dependent cell-mediated cytotoxicity but paradoxically weakens this effect via a form of IgG1 antibody-mediated immunogenic cell death [21] while upregulating immunosuppressive TGF-β expression in CRC [44].